Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Aventis describes adenosine A1 agonists with potential as antidiabetic agents

Feb. 13, 2004

New NPY Y5 antagonists and their use reported by Banyu

Feb. 13, 2004

Hyperleptinemia in lean ZDF rats reduces weight and converts white adipocytes into fat burning cells

Feb. 13, 2004

Launch of Climara Pro

Feb. 12, 2004

New glucokinase activators in early development at Novo Nordisk

Feb. 12, 2004

OATs mediate muscular side effects of HMG-CoA reductase inhibitors

Feb. 12, 2004

Replagal receives Canadian approval

Feb. 11, 2004

Takeda researchers prepare and test triazole-based DPP-IV inhibitors

Feb. 11, 2004

New ACAT and LDL oxidation inhibitors reported by Sankyo scientists

Feb. 11, 2004

Kyowa Hakko presents new antidiabetic agents

Feb. 11, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...